Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity
Restricted accessResearch articleFirst published online July, 2009
Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity
Detrusor overactivity is often observed in patients with multiple sclerosis (MS), and neurotoxins are emerging as second-line therapies albeit with different degrees of success per patient basis.
Objective
To investigate lower urinary tract (LUT) functional status and bladder innervation (calcitonin gene related peptide [CGRP] and substance P [SP] positive nerve fibers) in patients with MS.
Method
Eighteen MS patients with LUT symptoms underwent urodynamic investigations, and six non-MS patients undergoing cystoscopy due to microscopic hematuria served as controls. Cold cut bladder biopsies were taken from the bladder trigone region. Neurotransmitter expression was determined by individual immunohistochemical staining.
Results
Two distinct groups could be distinguished: group 1 with pronounced neurogenic detrusor overactivity and mild outflow obstruction; group 2 with some degree of neurogenic detrusor overactivity, detrusor hypocontractility during voiding, and high degree of an outflow obstruction. The presence of SP and CGRP immunoreactive + fiber density was observed in greater numbers in group 1.
Conclusion
Density of CGRP and SP positive nerve fibers within the urinary bladder of patients with MS may be suggestive of functional status of the lower urinary tract, namely denser innervation is observed in patients with mild outflow obstruction and strong detrusor overactivity. This observation could be useful when planning second-line treatment (neurotoxins) in these patients. Patients with denser innervation probably will respond better to such a therapy.
1 Altmann D . Evaluating the evidence for multiple sclerosis as an autoimmune disease. Arch Neurol2005; 62: 688.
2.
2 Bansil S Cook SD Rohowsky-Kochan C . Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol1995; 37(Suppl. 1): S87–S101.
3.
3 Bansil S Troiano R Rohowsky-Kochan C Jotkowitz A Dowling PC Cook SD . Multiple sclerosis: pathogenesis and treatment. Semin Neurol1994; 14: 146–153.
4.
4 Lassmann H . Experimental models of multiple sclerosis. Rev Neurol (Paris)2007; 163: 651–655.
5.
5 DasGupta R Fowler CJ . Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol2002; 15: 271–278.
6.
6 Hinson JL Boone TB . Urodynamics and multiple sclerosis. Urol Clin North Am1996; 23: 475–481.
7.
7 Janig W Morrison JF . Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Prog Brain Res1986; 67: 87–114.
8.
8 Miller H Simpson CA Yeates WK . Bladder dysfunction in multiple sclerosis. Br Med J1965; 1: 1265–1269.
9.
9 De Groat WC . Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol2006; 147(Suppl. 2): S25–S40.
10.
10 Fowler CJ Beck RO Gerrard S Betts CD Fowler CG . Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry1994; 57: 169–173.
11.
11 Kruse MN Mallory BS Noto H Roppolo JR de Groat WC . Modulation of the spinobulbospinal micturition reflex pathway in cats. Am J Physiol Regul Integr Comp Physiol1992; 262: R478–R484.
12.
12 Zinck ND Downie JW . Plasticity in the injured spinal cord: can we use it to advantage to reestablish effective bladder voiding and continence. Prog Brain Res2006; 152: 147–162.
13.
13 Avelino A Cruz C Nagy I Cruz F . Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience2002; 109: 787–798.
14.
14 Habler HJ Janig W Koltzenburg M . Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol1990; 425: 545–562.
15.
15 Davis KD Meyer RA Campbell JN . Chemosensitivity and sensitization of nociceptive afferents that innervate the hairy skin of monkey. J Neurophysiol1993; 69: 1071–1081.
16.
16 Handwerker HO Kilo S Reeh PW . Unresponsive afferent nerve fibres in the sural nerve of the rat. J Physiol1991; 435: 229–242.
17.
17 Kress M Koltzenburg M Reeh PW Handwerker HO . Responsiveness and functional attributes of electrically localized terminals of cutaneous C-fibers in vivo and in vitro. J Neurophysiol1992; 68: 581–595.
18.
18 Neugebauer V Schaible HG Schmidt RF . Sensitization of articular afferents to mechanical stimuli by bradykinin. Pflugers Arch1989; 415: 330–335.
19.
19 Schmidt RF . Novel classes of responsive and unresponsive C nociceptors in human skin. J Neurosci1995; 15: 333–341.
20.
20 Tuttle JB Steers WD Albo M Nataluk E . Neural input regulates tissue NGF and growth of the adult rat urinary bladder. J Auton Nerv Syst1994; 49: 147–158.
21.
21 De Groat WC Kawatani M Hisamitsu T . Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst1990; 30(Suppl. 7): S71–S77.
22.
22 De Groat WC Yoshimura N . Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res2006; 152: 59–84.
23.
23 Kim JC Kim DB Seo S Park YH Hwang T-K . Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int2004; 94: 915–918.
24.
24 Liu HT Chancellor MB Kuo HC . Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-a injection. Eur Urol2008; 30: 30.
25.
25 Lowe EM Anand P Terenghi G Williams-Chestnut RE Sinicropi DV Osborne JL . Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol1997; 79: 572–577.
26.
26 McMahon SB Koltzenburg M . Novel classes of nociceptors: beyond Sherrington. Trends Neurosci1990; 13: 199–201.
27.
27 Micera A Lambiase A Stampachiacchiere B Bonini S Bonini S Levi-Schaffer F . Nerve growth factor and tissue repair remodeling: trkA(NGFR) and p75(NTR), two receptors one fate. Cytokine Growth Factor Rev2007; 18: 245–256.
28.
28 Steers WD Kolbeck S Creedon D Tuttle JB . Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest1991; 88: 1709–1715.
29.
29 Sundin T Dahlstrom A Norlen L Svedmyr N . The sympathetic innervation and adrenoreceptor function of the human lower urinary tract in the normal state and after parasympathetic denervation. Invest Urol1977; 14: 322–328.
30.
30 Bjorling DE Beckman M Saban R . Neurogenic inflammation of the bladder. Adv Exp Med Biol2003; 539: 551–583.
31.
31 Lecci A Maggi CA . Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept2001; 101: 1–18.
32.
32 Pennefather JN Lecci A Candenas ML Patak E Pinto FM Maggi CA . Tachykinins and tachykinin receptors: a growing family. Life Sci2004; 74: 1445–1463.
33.
33 Saban MR Saban R Bjorling DE . Kinetics of peptide-induced release of inflammatory mediators by the urinary bladder. Br J Urol1997; 80: 742–747.
34.
34 Szallasi A . The vanilloid (capsaicin) receptor: receptor types and species differences. Gen Pharmacol1994; 25: 223–243.
35.
35 Brady CM Apostolidis A Harper M . Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. BJU Int2004; 93: 770–776.
36.
36 Fowler CJ Harper M Fry CH . Voiding and the sacral reflex arc: lessons from capsaicin instillation. Scand J Urol Nephrol2002; 210: 46–50.
37.
37 De Groat WC Nadelhaft I Milne RJ Booth AM Morgan C Thor K . Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J Auton Nerv Syst1981; 3: 135–160.
38.
38 Wyndaele J Kovindha A Madersbacher H Radziszewski P Ruffion A Schurch B . Neurologic urinary and faecal incontinence. In: Incontinence, Paris: France, Health Publication Ltd; 2009. p. 793.
39.
39 Fowler CJ Jewkes D McDonald WI Lynn B Degroat WC . (letter) Intravesical capsaicin for neurogenic bladder dysfunction. Lancet1992; 339: 1239.
40.
40 Dasgupta P Fowler CJ . Chillies: from antiquity to urology. Br J Urol1997; 80: 845–852.
41.
41 Francisco C Miguel G Carlos S Maria Edite R Antonio C Mario R . Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol1997; 157: 585–589.
42.
42 De Ridder D Chandiramani V Dasgupta P Van Poppel H Baert L Fowler CJ . Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. J Urol1997; 158: 2087–2092.
43.
43 De Seze M Wiart L De Seze MP . Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol2004; 171: 251–255.
44.
44 Apostolidis A Popat R Yiangou Y . Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol2005; 174: 977–982.
45.
45 Giannantoni A Mearini E Del Zingaro M Santaniello F Porena M . Botulinum a toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. BJU Int2008; 102(Suppl. 1): 2–6.
46.
46 MacDonald R Monga M Fink HA Wilt TJ . Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med2008; 31: 157–165.
47.
47 Van Poppel H Stessens R Baert L Van Damme B Carton H . Vasoactive intestinal polypeptidergic innervation of human urinary bladder in normal and pathological conditions. Urol Int1988; 43: 205–210.
48.
48 Moss H Tansey E Milner P Lincoln J Burnstock G . Neuropeptide immunoreactivity and choline acetyltransferase activity in the mouse urinary bladder following inoculation with Semliki Forest Virus. J Auton Nerv Syst1990; 31: 47–56.
49.
49 Pascual AM Martinez-Bisbal MC Bosca I . Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology2007; 69: 63–67.
50.
50 De Sèze M Wiart L Joseph PA Dosque JP Mazaux JM Barat M . Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn1998; 17: 513–523.
51.
51 Silva C Rio ME Cruz F . Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol2000; 38: 444–452.
52.
52 Dasgupta P Chandiramani VA Beckett A Scaravilli F Fowler CJ . The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyperreflexia. BJU Int2000; 85: 238–245.
53.
53 Yoshimura N De Groat WC . Plasticity of Na+ channels in afferent neurones innervating rat urinary bladder following spinal cord injury. J Physiol1997; 503: 269–276.
54.
54 Szallasi A . Autoradiographic visualization and pharmacological characterization of vanilloid (capsaicin) receptors in several species, including man. Acta Physiol Scand Suppl1995; 629: 1–68.
55.
55 Szallasi A Blumberg PM . Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev1999; 51: 159–212.
56.
56 Kobayashi K Fukuoka T Obata K . Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J Comp Neurol2005; 493: 596–606.
57.
57 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
58.
58 Lublin FD Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of new agents in multiple sclerosis. Neurology1996; 46: 907–911.
59.
59 Stohrer M Castro-Diaz D Chartier-Kastler E . Guidelines on neurogenic lower urinary tract dysfunction, In: European Association of Urology Guidelines. Arnhem, The Netherlands:European Association of Urology; 2009.
60.
60 Liu HT Kuo HC . Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn2009; 28: 78–81.
